Gefitinib (250mg)b . . . . . . .. . ..

GEFISTERIS 250
Gefitinib (250mg)
Gefitinib is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). It is classified as a tyrosine kinase inhibitor and works by blocking the activity of epidermal growth factor receptor (EGFR), a protein that is involved in the growth and spread of cancer cells.

Here are some key points about Gefitinib:

Indications: GEFISTERIS 250 is primarily used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific mutations in the EGFR gene. It is not recommended for patients without EGFR mutations.

Mechanism of Action: Gefitinib inhibits the tyrosine kinase activity of the EGFR, preventing the activation of downstream signaling pathways that promote cell growth and survival. In tumors with EGFR mutations, this targeted therapy can be effective in slowing down or inhibiting cancer cell growth.

Dosage: The typical dosage for gefitinib in the treatment of NSCLC is 250 mg taken orally once daily. The medication is usually taken on an empty stomach.

Monitoring: Regular monitoring for side effects and response to treatment is essential during gefitinib therapy. Patients may undergo imaging studies and other tests to assess the progression of the disease.

Common Side Effects: Common side effects of gefitinib include skin rash, diarrhea, nausea, and fatigue. Rash is often considered a positive sign that the drug is working. It is important to promptly inform healthcare providers about any severe or persistent side effects.

Contraindications and Precautions: Gefitinib is contraindicated in patients with a known hypersensitivity to the drug. It should be used with caution in patients with pre-existing interstitial lung disease.

EGFR Testing: Before prescribing gefitinib, healthcare providers often perform molecular testing to determine the presence of EGFR mutations in the patient's tumor. This information helps identify patients who are more likely to benefit from the drug.

As with any cancer treatment, patients should have open and detailed discussions with their healthcare providers about the potential benefits and risks of gefitinib. Treatment plans are often individualized based on factors such as the type of cancer, genetic mutations, overall health, and treatment history. Regular follow-up appointments are crucial for monitoring the response to treatment and managing any side effects.
Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 4 years we are dealing in Chronic Therapy and in 4 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us.
For further information please contact:
info@sterispharma.com
order now:
https://www.sterisonline.com/product/gefisteris-250-133658